[go: up one dir, main page]

PE20151652A1 - Proceso e intermedios para preparar un medicamento - Google Patents

Proceso e intermedios para preparar un medicamento

Info

Publication number
PE20151652A1
PE20151652A1 PE2015001956A PE2015001956A PE20151652A1 PE 20151652 A1 PE20151652 A1 PE 20151652A1 PE 2015001956 A PE2015001956 A PE 2015001956A PE 2015001956 A PE2015001956 A PE 2015001956A PE 20151652 A1 PE20151652 A1 PE 20151652A1
Authority
PE
Peru
Prior art keywords
intermediates
prepare
medicinal product
preparing
useful
Prior art date
Application number
PE2015001956A
Other languages
English (en)
Inventor
Philip Pye
Haim Cyril Ben
Matteo Conza
Ioannis Nicolaos Houpis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20151652A1 publication Critical patent/PE20151652A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se divulga un proceso para preparar los siguientes compuestos (I) y (II): donde R1, R1a y R2a son como se han definido en la memoria descriptiva, asi como tambien un proceso para preparar otros intermedios que pueden ser utiles para sintetizar productos posteriores, especialmente compuestos que son utiles como medicamentos, por ejemplo, inhibidores de la tirosina-cinasa de Bruton (Btk) tal como ibrutinib. Tambien se divulgan otros procesos, otros intermedios compuestos per se
PE2015001956A 2013-03-15 2014-03-11 Proceso e intermedios para preparar un medicamento PE20151652A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786842P 2013-03-15 2013-03-15
EP13159470 2013-03-15
EP13197813 2013-12-17

Publications (1)

Publication Number Publication Date
PE20151652A1 true PE20151652A1 (es) 2015-11-12

Family

ID=51535892

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001956A PE20151652A1 (es) 2013-03-15 2014-03-11 Proceso e intermedios para preparar un medicamento

Country Status (19)

Country Link
EP (1) EP2970291B1 (es)
JP (1) JP6777398B2 (es)
KR (2) KR102377688B1 (es)
CN (2) CN105026400A (es)
AU (2) AU2014230935A1 (es)
BR (1) BR112015021856A2 (es)
CA (1) CA2901510C (es)
DK (1) DK2970291T3 (es)
EA (1) EA201591685A1 (es)
ES (1) ES2924193T3 (es)
HR (1) HRP20220628T1 (es)
HU (1) HUE058914T2 (es)
LT (1) LT2970291T (es)
MX (2) MX380171B (es)
MY (1) MY194905A (es)
PE (1) PE20151652A1 (es)
SG (2) SG10201809696UA (es)
SI (1) SI2970291T1 (es)
WO (1) WO2014139970A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3196202B1 (en) 2011-09-02 2019-02-27 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
CN104447761A (zh) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 一种吡唑衍生物的制备方法
CN105481862B (zh) * 2015-01-21 2018-08-21 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途
EP3248979B1 (en) * 2015-01-21 2021-04-14 Hefei Institutes of Physical Science, Chinese Academy of Sciences Novel inhibitor of flt3 kinase and use thereof
PL3262046T3 (pl) * 2015-02-27 2021-05-04 Incyte Corporation Sole inhibitora pi3k i sposoby ich wytwarzania
LV15201B (lv) 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts Ibrutiniba izejvielas iegūšanas paņēmiens
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103058A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018145280A1 (zh) * 2017-02-09 2018-08-16 合肥合源药业有限公司 Flt3激酶抑制剂或其盐的晶型及其制备方法
CN107383017B (zh) * 2017-07-20 2020-01-14 河南师范大学 依鲁替尼高效制备方法
US20200369611A1 (en) 2017-08-01 2020-11-26 Boehringer Ingelheim International Gmbh Intermediate compounds and methods
CA3135211A1 (en) 2019-05-21 2020-11-26 Philip James Pye Processes and intermediates for preparing a btk inhibitor
CN113874378A (zh) * 2019-05-21 2021-12-31 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
CN113200987A (zh) * 2021-04-29 2021-08-03 湖南华腾制药有限公司 一种伊布替尼的制备方法
CN115322226B (zh) * 2022-08-17 2023-08-11 厦门大学 一种共价靶向砷抑制剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0014073A (pt) * 1999-09-17 2002-07-16 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapêuticos
PL2529621T3 (pl) * 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
WO2008054827A2 (en) * 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2139487B1 (en) * 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010112437A1 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2590982B1 (en) * 2010-07-09 2017-08-23 The Walter and Eliza Hall Institute of Medical Research Protein kinase inhibitors and methods of treatment
EP2632898A4 (en) * 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
WO2012158795A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
EA201490265A1 (ru) * 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
PE20150756A1 (es) * 2012-08-10 2015-06-03 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk
CA2888960C (en) * 2012-11-02 2017-08-15 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
HUE058914T2 (hu) 2022-09-28
AU2018204086B2 (en) 2020-03-12
HRP20220628T1 (hr) 2022-06-24
CA2901510C (en) 2022-11-29
AU2018204086A1 (en) 2018-06-28
MX380171B (es) 2025-03-12
DK2970291T3 (da) 2022-08-01
EP2970291B1 (en) 2022-05-11
JP6777398B2 (ja) 2020-10-28
MY194905A (en) 2022-12-22
KR20150132172A (ko) 2015-11-25
KR102311329B1 (ko) 2021-10-14
WO2014139970A1 (en) 2014-09-18
CA2901510A1 (en) 2014-09-18
EP2970291A1 (en) 2016-01-20
BR112015021856A2 (pt) 2017-07-18
SG10201809696UA (en) 2018-11-29
MX2020012596A (es) 2021-02-09
KR102377688B1 (ko) 2022-03-22
EA201591685A1 (ru) 2016-01-29
CN112608298A (zh) 2021-04-06
AU2014230935A1 (en) 2015-09-03
SG11201507595XA (en) 2015-10-29
CN105026400A (zh) 2015-11-04
ES2924193T3 (es) 2022-10-05
SI2970291T1 (sl) 2022-07-29
JP2016510779A (ja) 2016-04-11
LT2970291T (lt) 2022-06-10
KR20210123429A (ko) 2021-10-13
MX2015012731A (es) 2016-02-18

Similar Documents

Publication Publication Date Title
PE20151652A1 (es) Proceso e intermedios para preparar un medicamento
DOP2018000270A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2017005587A (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
DOP2017000304A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2018015212A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CL2015001307A1 (es) Proceso para preparar profármacos nucleósidos.
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
EP2824107A4 (en) ANSA-METALLOCEN COMPOUND AND METHOD FOR PRODUCING A SUPPORTED CATALYST THEREWITH
UY33950A (es) Inhibidores de benzodioxano de la producciòn de leucotrieno
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
SG10201804021TA (en) Methods of preparing inhibitors of influenza viruses replication
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
ECSP15013883A (es) Benzamidas
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
CR20180482A (es) Derivados de aminotiazol útiles como agentes antivíricos
BR112013003815A2 (pt) derivados de carboxamida cílicos substituódos e derivados de ureia como ligantes do receptor vaniloide
CO2017003004A2 (es) Nuevas triazolo[4,5-d]pirimidinas
BR112013020841A2 (pt) processo para preparar produtos que compreendem ativos estabilizados e composições que compreendem os mesmos
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same
NZ720106A (en) A process for the preparation of regadenoson